Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucio Cocco

Showing results (191-200 of 238) with videos related to

Pageof 24
Sort By:
Aging|June 4, 2020
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Advances in Biological Regulation|October 26, 2016
Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasisJames A McCubrey, Kvin Lertpiriyapong, Timothy L Fitzgerald, et al.
Advances in Biological Regulation|October 6, 2020
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signalingLinda S Steelman, William H Chappell, Shaw M Akula, et al.
Journal of Proteome Research|September 24, 2008
Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cellsVittoria Cenni, Jessika Bertacchini, Francesca Beretti, et al.
Cells|May 6, 2020
Targeting GSK3 and Associated Signaling Pathways Involved in CancerPrzemysław Duda, Shaw M Akula, Stephen L Abrams, et al.
Journal of Leukocyte Biology|May 16, 2015
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromesLucio Cocco, Carlo Finelli, Sara Mongiorgi, et al.
Frontiers in Oncology|June 10, 2021
"Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia"Stefano Ratti, Camilla Evangelisti, Sara Mongiorgi, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2024
Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human BloodAlessia De Stefano, Alessandra Cappellini, Irene Casalin, et al.
Advances in Biological Regulation|December 6, 2021
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53Stephen L Abrams, Shaw M Akula, Linda S Steelman, et al.
Pageof 24

Showing results (191-200 of 238) with videos related to

Sort By:
Pageof 24
Aging|June 4, 2020
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Advances in Biological Regulation|October 26, 2016
Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasisJames A McCubrey, Kvin Lertpiriyapong, Timothy L Fitzgerald, et al.
Advances in Biological Regulation|October 6, 2020
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signalingLinda S Steelman, William H Chappell, Shaw M Akula, et al.
Journal of Proteome Research|September 24, 2008
Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cellsVittoria Cenni, Jessika Bertacchini, Francesca Beretti, et al.
Cells|May 6, 2020
Targeting GSK3 and Associated Signaling Pathways Involved in CancerPrzemysław Duda, Shaw M Akula, Stephen L Abrams, et al.
Journal of Leukocyte Biology|May 16, 2015
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromesLucio Cocco, Carlo Finelli, Sara Mongiorgi, et al.
Frontiers in Oncology|June 10, 2021
"Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia"Stefano Ratti, Camilla Evangelisti, Sara Mongiorgi, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2024
Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human BloodAlessia De Stefano, Alessandra Cappellini, Irene Casalin, et al.
Advances in Biological Regulation|December 6, 2021
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53Stephen L Abrams, Shaw M Akula, Linda S Steelman, et al.
Pageof 24